AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's DiseasePRNewsWire • 10/28/21
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of PresbyopiaPRNewsWire • 10/26/21